



Dr. ZHOU Lihan
Co-founder & CEO, MiRXES Group

Lihan co-founded and serves as CEO of MiRXES, a Singapore headquartered, RNA centric biotechnology company with the mission to improve and save lives through early, actionable and personalized diagnosis. Lihan oversees MiRXES group's overall strategy and global operations in Singapore, USA, China and Japan with a team of 360 staff.

Prior to founding MiRXES in 2014, Lihan was a research scientist at the Bioprocessing Technology Institute, A*STAR where he co-developed a novel microRNA qPCR assay platform for microRNA biomarker and therapeutic target discovery. As a scientist-entrepreneur, Lihan is driving ground-breaking RNA research and actively champions a global ecosystem and standards to accelerate clinical adoption of RNA diagnostics.

Under Lihan's leadership, MiRXES was named Singapore's Most Promising Start-up in 2016 and Singapore's Fastest Growing Companies in 2018, 2019 and 2020. MiRXES has successfully raised USD \$130 million venture funding since 2016, which is among the highest raised by an Asia based genomics companies.

Lihan was recognized by the MIT Technology Review as a member of the Innovators Under 35 (2015). He was also awarded the A*STAR Scientist-Entrepreneur Award together with his co-founders in 2017, the NUS Outstanding Young Alumni Award and the EY Entrepreneur

of The Year™ Singapore awards (Overall Winner & Biotechnology category) in 2021. Lihan has been serving on the Board of Enterprise Singapore since April 2022.

Lihan obtained his Ph.D. in Biochemistry from Yong Loo Lin School of Medicine, National University of Singapore. He has authored and co-authored more than 25 peer-reviewed publications and several patent applications.